The RNA interference (RNAi) therapeutics market, which was once a specialized area, is now experiencing rapid growth. In 2023, the market reached USD 1.11 billion and is projected to expand significantly, with an impressive compound annual growth rate (CAGR) of 14.9%. By 2033, the market is expected to surge to USD 4.28 billion.
Small interfering RNA (siRNA) therapy is leading the way, accounting for 64% of the market share in 2023. Cancer treatment remains a key focus, with oncology applications set to dominate the market throughout the forecast period. North America was the leading region, holding a substantial 41% share of the market in 2023.
Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5115
Emerging Trends and Recent Changes in RNAi Therapeutics
RNA interference (RNAi) therapeutics started to gain momentum in clinical trials after 2008, a decade after the RNAi mechanism was first discovered. Since then, the number of clinical trials using RNAi-based drugs has grown significantly. From 2008 to 2022, the number of published clinical trials in this field increased nearly tenfold, and the number of ongoing trials surged about seven times between 2015 and 2021.
However, there was a noticeable decline in 2022, with a nearly 40% drop in ongoing trials involving small interfering RNA (siRNA) drugs. Despite this setback, siRNAs remain the dominant RNAi molecule used in clinical trials. In 2022, siRNAs made up about 90% of both published and ongoing trials, and this trend has continued into 2023, with nearly all current studies focusing on siRNA-based therapies.
In contrast, short hairpin RNAs (shRNAs) have been used less frequently but have maintained a steady presence in clinical trials over the years. Research involving shRNA-based treatments remains small but consistent. Similarly, studies exploring microRNAs (miRNAs) and miR-shRNAs are limited, with only a few publications and ongoing investigations in this area.
Recent Developments
In January 2023, the US FDA granted Breakthrough Therapy designation to Moderna’s new mRNA vaccine, mRNA-1345. This vaccine is designed to protect adults aged 60 and older from respiratory diseases caused by RSV infection.
In September 2022, Alnylam Pharmaceuticals, Inc. received approval from the European Commission to market their RNAi therapy, AMVUTTRA. This treatment is intended for adults with hereditary transthyretin-mediated (hATTR) polyneuropathy in stage 1 or stage 2.
Key Companies in the RNAi Therapeutics Market
- Alnylam Pharmaceuticals, Inc.
- Novartis
- Arbutus Biopharma
- Arrowhead Pharmaceuticals
- Novo Nordisk (Dicerna Pharmaceuticals)
- Sirnaomics
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/rnai-therapeutics-market-sizing
Access exclusive insight now @ https://www.towardshealthcare.com/price/5115
We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com
Web: https://www.towardshealthcare.com
Visit Dental Specifics: https://www.towardsdental.com
Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
